Literature DB >> 1550158

Cellular immunity of patients with recurrent or refractory vulvovaginal moniliasis.

I W Fong1, P McCleary, S Read.   

Abstract

Cellular immunity was studied in 73 patients with recurrent vaginal moniliasis and 37 healthy controls, by skin testing with the multitest CMI kit and Candida antigen, with measurement of lymphoblastic transformation to phytohemagglutinin, antigens of Candida albicans, mumps, and streptokinase. Eighteen patients (24.7%) had a hypoergic or anergic response to Candida antigen on skin testing versus two controls (5.4%), p = 0.01. Overall, the patient's lymphoblastic proliferation to mitogen and various antigens was not significantly different from that of the controls. However, a subgroup of younger women (19 to 29 years old) had impaired responses to Candida antigen when compared with age-matched controls, 58% versus 17%, p less than 0.005. Most women with current vaginal moniliasis had normal cellular immunity.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1550158     DOI: 10.1016/0002-9378(92)91356-f

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  22 in total

1.  Cell adhesion molecule and lymphocyte activation marker expression during experimental vaginal candidiasis.

Authors:  F L Wormley; J Chaiban; P L Fidel
Journal:  Infect Immun       Date:  2001-08       Impact factor: 3.441

Review 2.  Clinical and cost considerations in the pharmacotherapy of vulvovaginal candidiasis.

Authors:  I W Fong
Journal:  Pharmacoeconomics       Date:  1996-06       Impact factor: 4.981

Review 3.  Cytokines in the host response to Candida vaginitis: Identifying a role for non-classical immune mediators, S100 alarmins.

Authors:  Junko Yano; Mairi C Noverr; Paul L Fidel
Journal:  Cytokine       Date:  2011-12-17       Impact factor: 3.861

4.  Use of cellular depletion analysis to examine circulation of immune effector function between the vagina and the periphery.

Authors:  P L Fidel; W Luo; J Chabain; N A Wolf; E Van Buren
Journal:  Infect Immun       Date:  1997-09       Impact factor: 3.441

5.  Candida-specific Th1-type responsiveness in mice with experimental vaginal candidiasis.

Authors:  P L Fidel; M E Lynch; J D Sobel
Journal:  Infect Immun       Date:  1993-10       Impact factor: 3.441

6.  The value of prophylactic (monthly) clotrimazole versus empiric self-treatment in recurrent vaginal candidiasis.

Authors:  I W Fong
Journal:  Genitourin Med       Date:  1994-04

7.  Effects of systemic cell-mediated immunity on vaginal candidiasis in mice resistant and susceptible to Candida albicans infections.

Authors:  P L Fidel; J L Cutright; J D Sobel
Journal:  Infect Immun       Date:  1995-10       Impact factor: 3.441

Review 8.  Candida glabrata: review of epidemiology, pathogenesis, and clinical disease with comparison to C. albicans.

Authors:  P L Fidel; J A Vazquez; J D Sobel
Journal:  Clin Microbiol Rev       Date:  1999-01       Impact factor: 26.132

9.  Candida-specific cell-mediated immunity is demonstrable in mice with experimental vaginal candidiasis.

Authors:  P L Fidel; M E Lynch; J D Sobel
Journal:  Infect Immun       Date:  1993-05       Impact factor: 3.441

10.  Mice immunized by primary vaginal Candida albicans infection develop acquired vaginal mucosal immunity.

Authors:  P L Fidel; M E Lynch; D H Conaway; L Tait; J D Sobel
Journal:  Infect Immun       Date:  1995-02       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.